Notably, significant tumour growth inhibition was observed with 177Lu-EB-FAPI (an FAP-targeted therapeutic radiopharmaceutical) in human glioblastoma xenografts, suggesting the feasibility of FAP-targeted radioligand therapy in refractory and recurrent gliomas in future clinics 20. The gene discussed is FAP; the disease is glioblastoma.